Novo's Human Growth Hormone Patent Ruled Invalid, Unenforceable
A federal district court has found Danish drug maker Novo Nordisk's patent for recombinant human growth hormone invalid and unenforceable due to inequitable conduct....To view the full article, register now.
Already a subscriber? Click here to view full article